Showing 2321-2330 of 5696 results for "".
- Aviceda Announces Successful Completion of Key IND Toxicity Milestone with Favorable Safety Profile in Non-Human Primateshttps://modernod.com/news/aviceda-announces-successful-completion-of-key-ind-toxicity-milestone-with-favorable-safety-profile-in-non-human-primates/2481280/Aviceda Therapeutics announced completion of IND-enabling Good Laboratory Practice (GLP) toxicity studies in two species (total of 80 animals) as agreed upon in discussions with the FDA. Cambridge, Massachusetts-based Aviceda, has developed a proprietary nano-technology HALOS&
- iSTAR Medical Expands Commercial Rollout of MINIject with First Surgeries in Sweden and Norwayhttps://modernod.com/news/istar-medical-expands-commercial-rollout-of-miniject-with-first-surgeries-in-sweden-and-norway/2481272/iSTAR Medical announced that the commercial rollout expansion for MINIject has continued with the first implantations performed in Sweden and Norway. MINIject is iSTAR Medical’s minimally-invasive glaucoma surgery (MIGS) implant and is currently the only commerciall
- Kala Pharmaceuticals Submits of Investigational NDA for KPI-012 for the Treatment of Persistent Corneal Epithelial Defecthttps://modernod.com/news/kala-pharmaceuticals-submits-of-investigational-nda-for-kpi-012-for-the-treatment-of-persistent-corneal-epithelial-defect/2481262/Kala Pharmaceuticals announced the submission of an investigational new drug application (NDA) to the FDA for KPI-012 for the treatment of persistent corneal epithelial defect (PCED). Subject to acceptance of the IND by the FDA, Kala remains on-track to initiate a phase 2b cli
- BTIG to Host Ophthalmology Day on November 29, 2022https://modernod.com/news/btig-to-host-ophthalmology-day-on-november-29-2022/2481261/Global financial services firm BTIG announced that "Ophthalmology Day at BTIG" will take place on November 29, 2022. The virtual, 1-day event will include thematic panel discussions, one-on-one meetings and company presentations. The event will be hosted by:
- Meivertor Single-Handed Upper and Lower Eyelid Eversion Tool Now Availablehttps://modernod.com/news/meivertor-single-handed-upper-and-lower-eyelid-eversion-tool-now-available/2481259/Introduced at the American Academy of Optometry meeting in San Diego, the Meivertor is designed to be a simple solution for an everyday challenge: eversion of the upper eyelid to image the meibomian glands. "Having images of the meibomian glands is important to
- Graybug and CalciMedica Enter Into Definitive Merger Agreementhttps://modernod.com/news/graybug-and-calcimedica-enter-into-definitive-merger-agreement/2481257/Graybug Vision and CalciMedica announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on further developing CalciMedica’s lead product candidate Auxora, a proprietary, intr
- Kinarus Receives USPTO Notice of Allowance for Lead Therapeutic Candidate KIN001 for Retinal Diseaseshttps://modernod.com/news/kinarus-receives-uspto-notice-of-allowance-for-lead-therapeutic-candidate-kin001-for-retinal-diseases/2481256/Kinarus Therapeutics announced the receipt of a Notice of Allowability from the United States Patent and Trademark Office (USPTO) for US Patent Application No. 16/500,504 “Methods of preventing or treating Ophthalmic Diseases" covering its therapeutic candidate KIN001 in age-relat
- Bloomberg: Novartis Considering Sale of Ophthalmology Unithttps://modernod.com/news/bloomberg-novartis-considering-sale-of-ophthalmology-unit/2481246/Novartis is considering selling its non-core assets, including its ophthalmology franchise, to raise money for cutting-edge medicines, according to a Bloomberg
- Study: Vision Impairment is Associated with as Many as 100,000 US Dementia Caseshttps://modernod.com/news/study-vision-impairment-is-associated-with-as-many-as-100000-us-dementia-cases/2481238/Up to 100,000 US dementia cases could have potentially been prevented with improved eye care, according to a National Institute on Aging (NIA)-funded study published in JAMA Neurology. While the search for breakthrough drugs or interventions that could be treatments f
- FDA Accepts Tarsus' New Drug Application for TP-03 for Treatment of Demodex Blepharitishttps://modernod.com/news/fda-accepts-tarsus-new-drug-application-for-tp-03-for-treatment-of-demodex-blepharitis/2481235/As part of its third quarter earnings report, Tarsus Pharmaceuticals announced that the FDA has accepted the company's new drug application (NDA) for TP-03 for the treatment of Demodex blepharitis. The Prescription Drug User Fee Act (PDUFA) target action da